Skip to main content

Health Canada proposes regulatory changes to increase oversight for precursor chemicals and drug equipment

Health Canada has published a Notice of Intent to amend regulations for precursors and designated devices under the Controlled Drugs and Substances Act (CDSA), and they are inviting comments on the proposed measures. Until March 3, 2025, interested individuals may submit comments about the proposed measures, which are intended to:

  1. Make suspicious transaction reporting to Health Canada mandatory.
  2. Require licensed and registered companies to conduct criminal record and background checks on key personnel dealing with precursors.
  3. Apply condition-of-sale restrictions for ephedrine and pseudoephedrine (two precursors that can be used to produce methamphetamine).
  4. Expand registration requirements for designated devices to include the importation of component parts.
  5. Introduce new regulatory flexibilities so that Health Canada can respond to public health or public safety risks in a more agile and timely manner.

Further details about the proposed regulatory changes, as well as instructions for how to submit feedback, can be found here: Canada Gazette, Part 1, Volume 159, Number 5: GOVERNMENT NOTICES

Topic(s)

Other Government Departments (OGDs) Requirements
Acts & Regulations

Information source

Canada Gazette Publications
Disclaimer

The foregoing information is provided for informational purposes only and is not intended as, nor should it be considered, professional advice or a substitute for conducting your own thorough research and review. Before making any decisions or taking any action based on the information provided, you should conduct your own independent investigation and/or seek professional advice from a qualified expert in the relevant field. The CSCB disclaims all liability for actions taken or not taken based on the information provided.